Overview

Nivolumab 100 mg/10 mL is a programmed-death-1 (PD-1) inhibitor supplied as a ready-to-use solution whose value to institutional buyers depends as much on reliable cold-chain supply as on clinical activity. Sourcing teams must plan inventory around strict 2–8°C storage and multi-cycle treatment schedules to avoid interruption.

How It Works

Nivolumab is a fully human IgG4 monoclonal antibody that binds PD-1 on T cells, blocking engagement with PD-L1 and PD-L2 on tumor and myeloid cells. Releasing this checkpoint restores cytotoxic T-cell recognition of cancer cells. From a supply perspective the molecule is a temperature-sensitive biologic: every handoff from the manufacturer to the infusion chair must preserve the cold chain, so procurement decisions hinge on validated logistics rather than price alone.

Indications

Nivolumab is approved across multiple tumor types including melanoma, renal cell carcinoma, non-small cell lung cancer, and mismatch-repair-deficient colorectal cancer, used alone or with ipilimumab. Institutional demand therefore spans several departments, making consolidated purchasing and shared cold storage efficient for multi-specialty hospitals.

Dosage & Administration

Presented as 100 mg in 10 mL (10 mg/mL) solution for intravenous infusion, dosed by body weight or flat dose on a fixed schedule. Buyers should model consumption from patient weight bands and typical cycle length to size orders. Because it is a refrigerated biologic, partial vials and waste reduction through accurate demand forecasting directly improve cost efficiency.

Storage & Sourcing

Keep unopened vials at 2–8°C; do not freeze and protect from light. Use GDP-compliant refrigerated transport with continuous temperature logging, and quarantine shipments that breach the cold chain. For B2B contracts, negotiate buffer stock and rapid replenishment to cover multi-week treatment cycles without exposing product to temperature excursions.

FAQ

Q: What cold-chain conditions must Nivolumab shipments meet? A: Unopened vials require a sustained 2–8°C environment with light protection and data-logged transport; any excursion above this range should trigger quarantine and quality review before use.

Q: How should a buyer size MOQ for multi-department demand? A: Aggregate projected doses across all eligible indications by weight band and cycle, then order with a buffer for new starts while avoiding overstock that risks cold-chain expiry loss.

Q: Can Nivolumab 100 mg/10 mL be mixed with other infusion drugs? A: No. It is supplied as a separate solution for dedicated intravenous infusion and must not be co-administered in the same line with other products outside validated compatibility data.